Abstract
The relative failure of symptomatic therapeutic trials for Alzheimer's disease using non-selective cholinergic agonists brings about the need for longitudinal studies with parallel designs aimed at disease stabilization, using trophic substances or amyloid suppressors.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / psychology
-
Clinical Trials as Topic / methods
-
Humans
-
Parasympathomimetics / therapeutic use*
-
Prognosis
-
Psychiatric Status Rating Scales
-
Research Design
-
Treatment Outcome